Human Antibody Discovery Articles & Analysis
5 news found
"We are looking forward to working with Bristol Myers Squibb to demonstrate advantages of in vitro human antibody discovery with the EXIS platform." Kevin Chapman, PhD, CSO of Prellis, added, "The EXIS platform effectively breaks tolerance enabling direct discovery of human antibodies to ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. ...
Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its Externalized Immune System (EXIS™) platform, a first-in-class in vitro, fully human antibody discovery, and vaccine screening workflow. ...
In joining the Alloy network, those taking the hard path of drug discovery can know that they are not alone. We are in this together.” Through partnership, Alloy Therapeutics democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. Since its formation in 2017, ...
Alloy Therapeutics, founded in 2018 to empower scientists in the relentless pursuit of making better medicines for all, will provide BaseLaunch portfolio companies access to Alloy’s broad suite of antibody discovery platforms and services, including the ATX-Gx™ mouse platform, a suite of transgenic mice designed for best-in-class in vivo ...